NCT01532089 - Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 16, 2012

Primary Completion Date

February 13, 2018

Study Completion Date

August 18, 2020

Conditions

EGFR Exon 19 Deletion MutationEGFR NP_005219.2:p.L858RLung Non-Squamous Non-Small Cell CarcinomaStage IV Lung Non-Small Cell Cancer AJCC v7

Interventions

BIOLOGICAL

Bevacizumab

Given IV

DRUG

Erlotinib

Given PO

DRUG

Erlotinib Hydrochloride

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (19)

13057

Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse

13210

State University of New York Upstate Medical University, Syracuse

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

27710

Duke University Medical Center, Durham

29303

Upstate Carolina CCOP, Spartanburg

43210

Ohio State University Comprehensive Cancer Center, Columbus

48106

Michigan Cancer Research Consortium NCORP, Ann Arbor

49503

Cancer Research Consortium of West Michigan NCORP, Grand Rapids

54301

Saint Vincent Hospital Cancer Center Green Bay, Green Bay

55905

Mayo Clinic, Rochester

56303

Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud

57701

Rapid City Regional Hospital, Rapid City

58122

Sanford Broadway Medical Center, Fargo

61615

Illinois CancerCare-Peoria, Peoria

61801

Carle Cancer Center NCI Community Oncology Research Program, Urbana

62526

Heartland Cancer Research NCORP, Decatur

63110

Washington University School of Medicine, St Louis

92093

UC San Diego Moores Cancer Center, La Jolla

03106

New Hampshire Oncology Hematology PA-Hooksett, Hooksett

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Academic and Community Cancer Research United

OTHER